Novartis AG
OTC:NVSEF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novartis AG
OTC:NVSEF
|
CH |
|
Takamatsu Construction Group Co Ltd
OTC:TAKMF
|
JP |
|
Takeda Pharmaceutical Co Ltd
F:TKD
|
JP |
|
Vranken Pommery Monopole SA
F:9VP
|
FR |
|
U
|
United States Steel Corp
BMV:X
|
US |
|
O
|
Outlook Therapeutics Inc
SWB:41ON
|
US |
Wall St Price Targets
NVSEF Price Targets Summary
Novartis AG
According to Wall Street analysts, the average 1-year price target for NVSEF is 158.9 USD with a low forecast of 120.35 USD and a high forecast of 189.01 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NVSEF's stock price target?
Price Target
158.9
USD
According to Wall Street analysts, the average 1-year price target for NVSEF is 158.9 USD with a low forecast of 120.35 USD and a high forecast of 189.01 USD.
What is the Revenue forecast for Novartis AG?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 8 years is 2%.
What is the Gross Profit forecast for Novartis AG?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 1%. The projected CAGR for the next 8 years is 3%.
What is the Operating Income forecast for Novartis AG?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 8 years is 4%.
What is the Pre-Tax Income forecast for Novartis AG?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 3 years is 12%.
What is the Net Income forecast for Novartis AG?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 8 years is 5%.
